Switch to:
Also traded in: Germany, Switzerland, UK

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 9/10

vs
industry
vs
history
Cash to Debt No Debt
ISRG's Cash to Debt is ranked higher than
98% of the 316 Companies
in the Global Medical Devices industry.

( Industry Median: 2.30 vs. ISRG: No Debt )
Ranked among companies with meaningful Cash to Debt only.
ISRG' s Cash to Debt Range Over the Past 10 Years
Min: 6.35  Med: No Debt Max: No Debt
Current: No Debt
Equity to Asset 0.89
ISRG's Equity to Asset is ranked higher than
92% of the 294 Companies
in the Global Medical Devices industry.

( Industry Median: 0.63 vs. ISRG: 0.89 )
Ranked among companies with meaningful Equity to Asset only.
ISRG' s Equity to Asset Range Over the Past 10 Years
Min: 0.65  Med: 0.86 Max: 0.89
Current: 0.89
0.65
0.89
Interest Coverage No Debt
ISRG's Interest Coverage is ranked higher than
98% of the 221 Companies
in the Global Medical Devices industry.

( Industry Median: 97.42 vs. ISRG: No Debt )
Ranked among companies with meaningful Interest Coverage only.
ISRG' s Interest Coverage Range Over the Past 10 Years
Min: No Debt  Med: No Debt Max: No Debt
Current: No Debt
F-Score: 7
Z-Score: 25.53
M-Score: -2.64
WACC vs ROIC
8.83%
23.25%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 8/10

vs
industry
vs
history
Operating margin (%) 34.95
ISRG's Operating margin (%) is ranked higher than
98% of the 299 Companies
in the Global Medical Devices industry.

( Industry Median: 2.42 vs. ISRG: 34.95 )
Ranked among companies with meaningful Operating margin (%) only.
ISRG' s Operating margin (%) Range Over the Past 10 Years
Min: 25.56  Med: 35.7 Max: 40.3
Current: 34.95
25.56
40.3
Net-margin (%) 27.21
ISRG's Net-margin (%) is ranked higher than
96% of the 299 Companies
in the Global Medical Devices industry.

( Industry Median: 1.92 vs. ISRG: 27.21 )
Ranked among companies with meaningful Net-margin (%) only.
ISRG' s Net-margin (%) Range Over the Past 10 Years
Min: 19.65  Med: 25.86 Max: 30.14
Current: 27.21
19.65
30.14
ROE (%) 14.39
ISRG's ROE (%) is ranked higher than
79% of the 295 Companies
in the Global Medical Devices industry.

( Industry Median: 1.20 vs. ISRG: 14.39 )
Ranked among companies with meaningful ROE (%) only.
ISRG' s ROE (%) Range Over the Past 10 Years
Min: 12.17  Med: 18.96 Max: 21.36
Current: 14.39
12.17
21.36
ROA (%) 12.84
ISRG's ROA (%) is ranked higher than
90% of the 319 Companies
in the Global Medical Devices industry.

( Industry Median: 0.07 vs. ISRG: 12.84 )
Ranked among companies with meaningful ROA (%) only.
ISRG' s ROA (%) Range Over the Past 10 Years
Min: 10.59  Med: 16.51 Max: 18.44
Current: 12.84
10.59
18.44
ROC (Joel Greenblatt) (%) 161.45
ISRG's ROC (Joel Greenblatt) (%) is ranked higher than
97% of the 316 Companies
in the Global Medical Devices industry.

( Industry Median: 3.61 vs. ISRG: 161.45 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
ISRG' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: 117.99  Med: 186.03 Max: 245.9
Current: 161.45
117.99
245.9
Revenue Growth (3Y)(%) 6.80
ISRG's Revenue Growth (3Y)(%) is ranked higher than
64% of the 224 Companies
in the Global Medical Devices industry.

( Industry Median: 3.80 vs. ISRG: 6.80 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
ISRG' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: 0  Med: 18.65 Max: 57.1
Current: 6.8
0
57.1
EBITDA Growth (3Y)(%) 4.80
ISRG's EBITDA Growth (3Y)(%) is ranked higher than
52% of the 193 Companies
in the Global Medical Devices industry.

( Industry Median: 4.10 vs. ISRG: 4.80 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
ISRG' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -62.8  Med: 29.4 Max: 318.7
Current: 4.8
-62.8
318.7
EPS Growth (3Y)(%) 3.80
ISRG's EPS Growth (3Y)(%) is ranked higher than
53% of the 190 Companies
in the Global Medical Devices industry.

( Industry Median: 2.40 vs. ISRG: 3.80 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
ISRG' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -61.5  Med: 20.9 Max: 76.8
Current: 3.8
-61.5
76.8
GuruFocus has detected 5 Warning Signs with Intuitive Surgical Inc $ISRG.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» ISRG's 10-Y Financials

Financials (Next Earnings Date: 2017-04-19)


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

Q1 2016

ISRG Guru Trades in Q1 2016

Pioneer Investments 6,794 sh (New)
Ray Dalio 6,124 sh (+202.57%)
Eaton Vance Worldwide Health Sciences Fund 84,000 sh (+5.00%)
Steven Cohen Sold Out
Louis Moore Bacon Sold Out
Jim Simons 107,770 sh (-1.28%)
Jeremy Grantham 75,598 sh (-2.93%)
Vanguard Health Care Fund 456,850 sh (-12.14%)
Robert Olstein 9,400 sh (-14.55%)
Manning & Napier Advisors, Inc 195,125 sh (-63.96%)
Paul Tudor Jones 600 sh (-66.67%)
» More
Q2 2016

ISRG Guru Trades in Q2 2016

RS Investment Management 10,680 sh (New)
Steven Cohen 13,500 sh (New)
Joel Greenblatt 13,254 sh (New)
Jeremy Grantham 91,193 sh (+20.63%)
Eaton Vance Worldwide Health Sciences Fund 110,000 sh (+30.95%)
Paul Tudor Jones Sold Out
Ray Dalio Sold Out
Vanguard Health Care Fund 428,750 sh (-6.15%)
Manning & Napier Advisors, Inc 175,705 sh (-9.95%)
Robert Olstein 8,000 sh (-14.89%)
Pioneer Investments 3,708 sh (-45.42%)
Jim Simons 32,238 sh (-70.09%)
» More
Q3 2016

ISRG Guru Trades in Q3 2016

Ray Dalio 7,400 sh (New)
Lee Ainslie 1,750 sh (New)
Jim Simons 82,270 sh (+155.20%)
Pioneer Investments 3,708 sh (unchged)
Joel Greenblatt Sold Out
Manning & Napier Advisors, Inc 165,220 sh (-5.97%)
Robert Olstein 7,000 sh (-12.50%)
Jeremy Grantham 69,164 sh (-24.16%)
Vanguard Health Care Fund 243,169 sh (-43.28%)
Steven Cohen 3,900 sh (-71.11%)
Eaton Vance Worldwide Health Sciences Fund 56,174 sh (-48.93%)
» More
Q4 2016

ISRG Guru Trades in Q4 2016

Joel Greenblatt 2,698 sh (New)
John Paulson 10,100 sh (New)
Paul Tudor Jones 1,208 sh (New)
John Hussman 10,000 sh (New)
Ron Baron 11,216 sh (New)
Steven Cohen 12,200 sh (+212.82%)
Jim Simons 199,891 sh (+142.97%)
Robert Olstein 12,300 sh (+75.71%)
Pioneer Investments 5,081 sh (+37.03%)
Lee Ainslie 1,750 sh (unchged)
Steven Cohen 20,000 sh (unchged)
Eaton Vance Worldwide Health Sciences Fund 56,174 sh (unchged)
Manning & Napier Advisors, Inc 159,680 sh (-3.35%)
Jeremy Grantham 53,233 sh (-23.03%)
Vanguard Health Care Fund 186,869 sh (-23.15%)
Ray Dalio 1,700 sh (-77.03%)
» More
» Details

Insider Trades

Latest Guru Trades with ISRG

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Medical Devices » Medical Devices    NAICS: 339113    SIC: 3841
Compare:NYSE:ZBH, NYSE:STJ, NYSE:BSX, NYSE:EW, OTCPK:SNNUF, NYSE:SYK, OTCPK:SONVY, NAS:ALGN, NYSE:TFX, NYSE:VAR, OTCPK:SDMHF, OTCPK:CHEOY, OTCPK:CNVVY, NAS:ABMD, NAS:NUVA, NAS:MASI, OTCPK:FSPKF, OTCPK:EKTAY, NAS:IART, OTCPK:GGNDF » details
Traded in other countries:IUI1.Germany, ISRG.Switzerland, 0R29.UK,
Intuitive Surgical Inc designs, manufactures and markets da Vinci Surgical Systems and related instruments and accessories.

Intuitive Surgical Inc is a Delaware corporation founded in 1995. The Company designs, manufactures and markets da Vinci Surgical Systems and related instruments and accessories. A da Vinci Surgical System consists of a surgeon's console, a patient-side cart, and a high performance vision system. da Vinci Surgery utilizes computational, robotic and imaging technologies to enable improved patient outcomes compared to other surgical and non-surgical therapies. The Company has commercialized four generations of da Vinci Surgical System- the da Vinci Xi Surgical System, the da Vinci Si Surgical System, the da Vinci S Surgical System and the standard da Vinci Surgical System. da Vinci Surgical Systems are comprised of the following components: Surgeon's Console. The da Vinci Surgical System allows surgeons to operate while comfortably seated at an ergonomic console viewing a 3-D image of the surgical field. Patient-Side Cart. The patient-side cart holds electromechanical arms that manipulate the instruments inside the patient. 3-D Vision System. Its vision system includes its InSite 3-D endoscope with two separate vision channels linked to two separate color monitors through high performance video cameras and specialized image processing hardware. da Vinci Skills Simulator. The Skills Simulator is a practice tool that gives a user the opportunity to practice his or her facility with the surgeon console controls. EndoWrist instruments are offered in a variety of sizes, of which 5mm and 8mm diameter sizes are commonly sold. The Company provides its products through a direct sales organization in the U.S, mainly of Western Europe excluding Spain, Portugal, Italy and Greece; Japan and Korea. The Company's products and operations are subject to rigorous regulation by the FDA, the State of California and countries or regions in which the company markets its products.

Guru Investment Theses on Intuitive Surgical Inc

Baron Opportunity Fund Comments on Intuitive Surgical - Feb 21, 2017

Intuitive Surgical (NASDAQ:ISRG) manufactures and markets the da Vinci Surgical System, a robotic surgical system consisting of a surgeon’s console, a patient-side cart, a high performance vision system and proprietary “wristed” instruments and surgical accessories. The da Vinci system seamlessly translates the surgeon’s natural hand movements on instrument controls at the console into corresponding micro-movements of instruments inserted into the patient through small puncture incisions or ports. The da Vinci provides the surgeon with the intuitive control, range of motion, fine tissue manipulation capability and 3-D vision characteristics of open surgery, while simultaneously allowing the surgeon to work through the small ports of minimally-invasive surgery. Patients treated with the da Vinci system benefit from improved clinical results, smaller incisions, fewer complications, less blood loss, less nerve damage, reduced pain and faster recovery compared with open surgery. The company is targeting four million annual surgical procedures worldwide and, we believe, this target is likely to increase over time. In 2016, roughly 750,000 procedures were performed using Intuitive’s robotic systems, implying substantial runway for growth.



From Baron Funds' Baron Opportunity Fund fourth quarter 2016 commentary.



Check out Ron Baron latest stock trades

Baron Funds' Fifth Avenue Growth Fund Comments on Intuitive Surgical - Feb 13, 2017

After a multi-year hiatus, we re-initiated an investment in Intuitive Surgical, Inc. (NASDAQ:ISRG) Intuitive sells the da Vinci robotic surgical system, which enables surgeons to perform minimally-invasive surgery in a number of different procedure categories. Minimally-invasive surgery benefits patients because they generally experience less pain and faster recovery after the procedure. Intuitive has held an effective monopoly on robotic-assisted surgery for many years. We believe the company has durable competitive advantages consisting of patents, technology, regulatory approvals, a worldwide installed base of systems, large salesforce, and balance sheet with over $4 billion in net cash. Although Intuitive is expected to face competitors in the future, we believe it will be difficult for competitors to displace the company and the company will maintain its leadership position. In 2016, roughly 750,000 procedures were performed worldwide using Intuitive’s robotic systems, an increase of 15% year-over-year. Intuitive generates revenue from instruments/accessories every time a procedure is performed using its robotic system, which together with annual service fees provides recurring revenue. Management has defined its current addressable market as four million procedures, but we believe Intuitive will continue to expand its addressable market by entering new procedure areas. The company has an exciting pipeline of new products, including a single port system that will enable new procedures and a robotic catheter system that will enable lung tissue biopsies to be taken minimally invasively. In the fourth quarter, the stock pulled back despite a strong fundamental outlook because investors became concerned that the repeal of the Affordable Care Act would cause Intuitive’s hospital customers to cut capital spending, which would negatively impact Intuitive’s system sales. We saw this pull-back as short-sighted and bought the stock. We think Intuitive can grow revenue and earnings at attractive rates over the long term.



From Baron Funds' Fifth Avenue Growth Fund fourth quarter 2016 commentary.



Check out Ron Baron latest stock trades

Top Ranked Articles about Intuitive Surgical Inc

Baron Opportunity Fund Comments on Intuitive Surgical Guru stock highlight
Intuitive Surgical (NASDAQ:ISRG) manufactures and markets the da Vinci Surgical System, a robotic surgical system consisting of a surgeon’s console, a patient-side cart, a high performance vision system and proprietary “wristed” instruments and surgical accessories. The da Vinci system seamlessly translates the surgeon’s natural hand movements on instrument controls at the console into corresponding micro-movements of instruments inserted into the patient through small puncture incisions or ports. The da Vinci provides the surgeon with the intuitive control, range of motion, fine tissue manipulation capability and 3-D vision characteristics of open surgery, while simultaneously allowing the surgeon to work through the small ports of minimally-invasive surgery. Patients treated with the da Vinci system benefit from improved clinical results, smaller incisions, fewer complications, less blood loss, less nerve damage, reduced pain and faster recovery compared with open surgery. The company is targeting four million annual surgical procedures worldwide and, we believe, this target is likely to increase over time. In 2016, roughly 750,000 procedures were performed using Intuitive’s Read more...
Baron Funds' Fifth Avenue Growth Fund Comments on Intuitive Surgical Guru stock highlight
After a multi-year hiatus, we re-initiated an investment in Intuitive Surgical, Inc. (NASDAQ:ISRG) Intuitive sells the da Vinci robotic surgical system, which enables surgeons to perform minimally-invasive surgery in a number of different procedure categories. Minimally-invasive surgery benefits patients because they generally experience less pain and faster recovery after the procedure. Intuitive has held an effective monopoly on robotic-assisted surgery for many years. We believe the company has durable competitive advantages consisting of patents, technology, regulatory approvals, a worldwide installed base of systems, large salesforce, and balance sheet with over $4 billion in net cash. Although Intuitive is expected to face competitors in the future, we believe it will be difficult for competitors to displace the company and the company will maintain its leadership position. In 2016, roughly 750,000 procedures were performed worldwide using Intuitive’s robotic systems, an increase of 15% year-over-year. Intuitive generates revenue from instruments/accessories every time a procedure is performed Read more...
What Is Value? A discussion on intrinsic value
In a recent article one of the best writers on GuruFocus, Geoff Gannon, wrote the following: "The value investor in me – the stuff I learned from the books I read in my teens – rebels against the idea of paying a high (price-earnings) P/E for anything. That’s a mistake. It’s better to pay 30 times earnings for a company like Luxottica (NYSE:LUX) than 10 times earnings for a company like Weight Watchers (NYSE:WTW)." Read more...
Top Medical Companies Reach High Financial Strength A study of Altman Z-scores, Part 3: NYSE and Nasdaq companies have wider scores
Among all stocks trading on the New York Stock Exchange and Nasdaq, two medical companies, Intuitive Surgical Inc. (NASDAQ:ISRG) and Anika Therapeutics Inc. (NASDAQ:ANIK), have relatively strong Altman Z-scores. Read more...
Weekly CFO Sells Highlight Recent insider sells from company CFOs
According to GuruFocus Insider Data, the recent CFO sells were: Ross Stores Inc. (NASDAQ:ROST), Intuitive Surgical Inc. (NASDAQ:ISRG) and Facebook Inc. (NASDAQ:FB). Read more...
Weekly CFO Sells Highlight Insiders sell Honeywell, Intuitive Surgical, Michaels
According to GuruFocus Insider Data, the recent CFO sells were: Honeywell International Inc. (NYSE:HON), Intuitive Surgical Inc. (NASDAQ:ISRG) and The Michaels Companies Inc. (NASDAQ:MIK). Read more...
Weekly CFO Sells Highlights Workday, Intuitive Surgical, Priceline Group top list
According to GuruFocus Insider Data, the recent CFO sells were: Workday Inc. (NYSE:WDAY), Intuitive Surgical Inc. (NASDAQ:ISRG) and Priceline Group Inc. (NASDAQ:PCLN). Read more...

Ratios

vs
industry
vs
history
P/E(ttm) 39.06
ISRG's P/E(ttm) is ranked lower than
67% of the 172 Companies
in the Global Medical Devices industry.

( Industry Median: 25.50 vs. ISRG: 39.06 )
Ranked among companies with meaningful P/E(ttm) only.
ISRG' s P/E(ttm) Range Over the Past 10 Years
Min: 17.77  Med: 37.38 Max: 107.2
Current: 39.06
17.77
107.2
Forward P/E 31.15
ISRG's Forward P/E is ranked lower than
68% of the 56 Companies
in the Global Medical Devices industry.

( Industry Median: 23.92 vs. ISRG: 31.15 )
Ranked among companies with meaningful Forward P/E only.
N/A
PE(NRI) 39.06
ISRG's PE(NRI) is ranked lower than
66% of the 168 Companies
in the Global Medical Devices industry.

( Industry Median: 25.48 vs. ISRG: 39.06 )
Ranked among companies with meaningful PE(NRI) only.
ISRG' s PE(NRI) Range Over the Past 10 Years
Min: 17.77  Med: 37.38 Max: 107.2
Current: 39.06
17.77
107.2
Price/Owner Earnings (ttm) 37.37
ISRG's Price/Owner Earnings (ttm) is ranked lower than
64% of the 103 Companies
in the Global Medical Devices industry.

( Industry Median: 30.29 vs. ISRG: 37.37 )
Ranked among companies with meaningful Price/Owner Earnings (ttm) only.
ISRG' s Price/Owner Earnings (ttm) Range Over the Past 10 Years
Min: 18.18  Med: 40.86 Max: 110.28
Current: 37.37
18.18
110.28
P/B 4.91
ISRG's P/B is ranked lower than
68% of the 321 Companies
in the Global Medical Devices industry.

( Industry Median: 3.17 vs. ISRG: 4.91 )
Ranked among companies with meaningful P/B only.
ISRG' s P/B Range Over the Past 10 Years
Min: 2.81  Med: 6 Max: 15.72
Current: 4.91
2.81
15.72
P/S 10.61
ISRG's P/S is ranked lower than
85% of the 307 Companies
in the Global Medical Devices industry.

( Industry Median: 3.29 vs. ISRG: 10.61 )
Ranked among companies with meaningful P/S only.
ISRG' s P/S Range Over the Past 10 Years
Min: 4.16  Med: 9.74 Max: 24.28
Current: 10.61
4.16
24.28
PFCF 28.99
ISRG's PFCF is ranked lower than
53% of the 106 Companies
in the Global Medical Devices industry.

( Industry Median: 27.61 vs. ISRG: 28.99 )
Ranked among companies with meaningful PFCF only.
ISRG' s PFCF Range Over the Past 10 Years
Min: 18.41  Med: 31.6 Max: 119.58
Current: 28.99
18.41
119.58
POCF 27.50
ISRG's POCF is ranked lower than
68% of the 135 Companies
in the Global Medical Devices industry.

( Industry Median: 18.12 vs. ISRG: 27.50 )
Ranked among companies with meaningful POCF only.
ISRG' s POCF Range Over the Past 10 Years
Min: 11.34  Med: 27.43 Max: 84.53
Current: 27.5
11.34
84.53
EV-to-EBIT 26.77
ISRG's EV-to-EBIT is ranked lower than
59% of the 169 Companies
in the Global Medical Devices industry.

( Industry Median: 21.48 vs. ISRG: 26.77 )
Ranked among companies with meaningful EV-to-EBIT only.
ISRG' s EV-to-EBIT Range Over the Past 10 Years
Min: 10.2  Med: 26.5 Max: 74.4
Current: 26.77
10.2
74.4
EV-to-EBITDA 24.40
ISRG's EV-to-EBITDA is ranked lower than
69% of the 175 Companies
in the Global Medical Devices industry.

( Industry Median: 15.79 vs. ISRG: 24.40 )
Ranked among companies with meaningful EV-to-EBITDA only.
ISRG' s EV-to-EBITDA Range Over the Past 10 Years
Min: 9.5  Med: 24 Max: 60.8
Current: 24.4
9.5
60.8
PEG 9.92
ISRG's PEG is ranked lower than
84% of the 76 Companies
in the Global Medical Devices industry.

( Industry Median: 2.33 vs. ISRG: 9.92 )
Ranked among companies with meaningful PEG only.
ISRG' s PEG Range Over the Past 10 Years
Min: 0.15  Med: 1 Max: 18.34
Current: 9.92
0.15
18.34
Shiller P/E 60.84
ISRG's Shiller P/E is ranked lower than
63% of the 49 Companies
in the Global Medical Devices industry.

( Industry Median: 49.62 vs. ISRG: 60.84 )
Ranked among companies with meaningful Shiller P/E only.
ISRG' s Shiller P/E Range Over the Past 10 Years
Min: 44.08  Med: 63.11 Max: 282.23
Current: 60.84
44.08
282.23
Current Ratio 5.45
ISRG's Current Ratio is ranked higher than
81% of the 313 Companies
in the Global Medical Devices industry.

( Industry Median: 2.45 vs. ISRG: 5.45 )
Ranked among companies with meaningful Current Ratio only.
ISRG' s Current Ratio Range Over the Past 10 Years
Min: 3.02  Med: 4.55 Max: 5.45
Current: 5.45
3.02
5.45
Quick Ratio 5.14
ISRG's Quick Ratio is ranked higher than
84% of the 313 Companies
in the Global Medical Devices industry.

( Industry Median: 1.79 vs. ISRG: 5.14 )
Ranked among companies with meaningful Quick Ratio only.
ISRG' s Quick Ratio Range Over the Past 10 Years
Min: 2.68  Med: 4.24 Max: 5.14
Current: 5.14
2.68
5.14
Days Inventory 77.63
ISRG's Days Inventory is ranked higher than
75% of the 281 Companies
in the Global Medical Devices industry.

( Industry Median: 130.88 vs. ISRG: 77.63 )
Ranked among companies with meaningful Days Inventory only.
ISRG' s Days Inventory Range Over the Past 10 Years
Min: 55.48  Med: 74.23 Max: 91.85
Current: 77.63
55.48
91.85
Days Sales Outstanding 58.06
ISRG's Days Sales Outstanding is ranked higher than
64% of the 266 Companies
in the Global Medical Devices industry.

( Industry Median: 66.78 vs. ISRG: 58.06 )
Ranked among companies with meaningful Days Sales Outstanding only.
ISRG' s Days Sales Outstanding Range Over the Past 10 Years
Min: 48.57  Med: 61.96 Max: 79.2
Current: 58.06
48.57
79.2
Days Payable 30.70
ISRG's Days Payable is ranked lower than
78% of the 254 Companies
in the Global Medical Devices industry.

( Industry Median: 58.05 vs. ISRG: 30.70 )
Ranked among companies with meaningful Days Payable only.
ISRG' s Days Payable Range Over the Past 10 Years
Min: 23.81  Med: 32.39 Max: 58.29
Current: 30.7
23.81
58.29

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -0.50
ISRG's 3-Year Average Share Buyback Ratio is ranked higher than
72% of the 199 Companies
in the Global Medical Devices industry.

( Industry Median: -3.90 vs. ISRG: -0.50 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
ISRG' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -115.5  Med: -2.1 Max: 2.4
Current: -0.5
-115.5
2.4

Valuation & Return

vs
industry
vs
history
Price/Net Cash 15.36
ISRG's Price/Net Cash is ranked higher than
53% of the 114 Companies
in the Global Medical Devices industry.

( Industry Median: 17.13 vs. ISRG: 15.36 )
Ranked among companies with meaningful Price/Net Cash only.
ISRG' s Price/Net Cash Range Over the Past 10 Years
Min: 4.47  Med: 20.42 Max: 60.45
Current: 15.36
4.47
60.45
Price/Net Current Asset Value 11.15
ISRG's Price/Net Current Asset Value is ranked lower than
66% of the 234 Companies
in the Global Medical Devices industry.

( Industry Median: 6.59 vs. ISRG: 11.15 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
ISRG' s Price/Net Current Asset Value Range Over the Past 10 Years
Min: 3.7  Med: 10.87 Max: 28.33
Current: 11.15
3.7
28.33
Price/Tangible Book 5.11
ISRG's Price/Tangible Book is ranked lower than
58% of the 283 Companies
in the Global Medical Devices industry.

( Industry Median: 4.24 vs. ISRG: 5.11 )
Ranked among companies with meaningful Price/Tangible Book only.
ISRG' s Price/Tangible Book Range Over the Past 10 Years
Min: 3.5  Med: 5.41 Max: 16.47
Current: 5.11
3.5
16.47
Price/Projected FCF 2.20
ISRG's Price/Projected FCF is ranked lower than
53% of the 123 Companies
in the Global Medical Devices industry.

( Industry Median: 2.11 vs. ISRG: 2.20 )
Ranked among companies with meaningful Price/Projected FCF only.
ISRG' s Price/Projected FCF Range Over the Past 10 Years
Min: 1.5  Med: 2.3 Max: 14.57
Current: 2.2
1.5
14.57
Price/DCF (Earnings Based) 1.37
ISRG's Price/DCF (Earnings Based) is ranked higher than
82% of the 22 Companies
in the Global Medical Devices industry.

( Industry Median: 2.17 vs. ISRG: 1.37 )
Ranked among companies with meaningful Price/DCF (Earnings Based) only.
N/A
Price/Median PS Value 1.09
ISRG's Price/Median PS Value is ranked lower than
58% of the 262 Companies
in the Global Medical Devices industry.

( Industry Median: 0.99 vs. ISRG: 1.09 )
Ranked among companies with meaningful Price/Median PS Value only.
ISRG' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.32  Med: 0.94 Max: 2.15
Current: 1.09
0.32
2.15
Price/Graham Number 2.98
ISRG's Price/Graham Number is ranked lower than
65% of the 139 Companies
in the Global Medical Devices industry.

( Industry Median: 2.06 vs. ISRG: 2.98 )
Ranked among companies with meaningful Price/Graham Number only.
ISRG' s Price/Graham Number Range Over the Past 10 Years
Min: 2.13  Med: 3.52 Max: 7.99
Current: 2.98
2.13
7.99
Earnings Yield (Greenblatt) (%) 3.77
ISRG's Earnings Yield (Greenblatt) (%) is ranked higher than
71% of the 337 Companies
in the Global Medical Devices industry.

( Industry Median: -0.30 vs. ISRG: 3.77 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
ISRG' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: 1.3  Med: 3.8 Max: 9.8
Current: 3.77
1.3
9.8
Forward Rate of Return (Yacktman) (%) 5.11
ISRG's Forward Rate of Return (Yacktman) (%) is ranked lower than
60% of the 123 Companies
in the Global Medical Devices industry.

( Industry Median: 8.88 vs. ISRG: 5.11 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) (%) only.
ISRG' s Forward Rate of Return (Yacktman) (%) Range Over the Past 10 Years
Min: -0.1  Med: 29.7 Max: 141.9
Current: 5.11
-0.1
141.9

More Statistics

Revenue (TTM) (Mil) $2,704
EPS (TTM) $ 18.72
Beta0.85
Short Percentage of Float9.33%
52-Week Range $543.40 - 733.17
Shares Outstanding (Mil)38.79

Analyst Estimate

Dec17 Dec18
Revenue (Mil $) 2,960 3,286
EPS ($) 23.99 26.75
EPS w/o NRI ($) 23.99 26.75
EPS Growth Rate
(3Y to 5Y Estimate)
15.60%
Dividends Per Share ($)
» More Articles for ISRG

Headlines

Articles On GuruFocus.com
Baron Opportunity Fund Comments on Intuitive Surgical Feb 21 2017 
Baron Funds' Fifth Avenue Growth Fund Comments on Intuitive Surgical Feb 13 2017 
John Hussman’s Top 3 New Holdings Feb 02 2017 
What Is Value? Nov 11 2016 
Classic Value Investing vs. Dynamic Value Investing Nov 02 2016 
Olstein All Cap Value Fund 2nd Quarter Letter to Shareholders Sep 01 2016 
Eaton Vance Worldwide Health Sciences Fund 2nd Quarter Commentary Aug 04 2016 
Sam Isaly's Top Investments of the Year Aug 01 2016 
Titan Medical: Greatly Undervalued Jul 20 2016 
Top Medical Companies Reach High Financial Strength Jul 19 2016 

More From Other Websites
Stocks Rally Broadly; Will These 5 Large Caps Turn Into Big Leaders? Feb 21 2017
Baron Opportunity Fund Comments on Intuitive Surgical Feb 21 2017
Baron Opportunity Fund Shareholder 4th Quarter Commentary Feb 21 2017
Top Analyst Upgrades and Downgrades: Intuitive Surgical, Restaurant Brands, Scorpio Tankers, Teva,... Feb 14 2017
Intuitive Surgical Reports New Employee Option Grants for February 2017 Feb 13 2017
Baron Funds' Fifth Avenue Growth Fund Comments on Intuitive Surgical Feb 13 2017
Baron Funds' Baron Fifth Avenue Growth Fund 4th Quarter Commentary Feb 13 2017
INTUITIVE SURGICAL INC Financials Feb 09 2017
INTUITIVE SURGICAL INC Files SEC form 8-K, Change in Directors or Principal Officers Feb 08 2017
INTUITIVE SURGICAL INC Files SEC form 10-K, Annual Report Feb 06 2017
ETFs with exposure to Intuitive Surgical, Inc. : February 2, 2017 Feb 02 2017
Morgan Dempsey Capital Management Llc Buys Target Corp, Cisco Systems Inc, Reynolds American ... Jan 26 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)